# Viscient Bio Inc

> Viscient Bio is a privately held San Diego biotechnology company using 3D human tissue models and multi-omics to discover and develop drugs, initially for metabolic liver disease. Its wager is practical: reproduce human disease in a dish, identify the pathways driving it, and use that model to reject weak candidates before expensive clinical trials. The company has reported an unnamed oral small-molecule candidate for MASH and published peer-reviewed validation of its human-cell liver model, while operating with a team listed publicly at 2-10 people.

- **Founded:** 2017
- **Headquarters:** San Diego, United States
- **Founders:** Keith Murphy (Founder, CEO and Chairman), Jeffrey N. Miner (Co-founder and Chief Scientific Officer)
- **Team size:** 2-10 employees; nine employees were visible on LinkedIn when researched
- **Products:** 3D human liver disease model, MASH small-molecule program, Drug discovery and preclinical evaluation platform
- **Notable:** Published a peer-reviewed 2024 study showing that bioprinted tissue made from MASH-diseased donor cells developed increased fibrosis versus healthy-donor tissue without artificial disease-inducing agents., Reported in 2023 that its model reproduced the clinical direction of selected successful and failed MASH compounds in retrospective testing., Identified an unnamed oral small-molecule MASH candidate from a target discovered primarily with 3D tissue models and advanced it to preclinical study.

## Products & services

- **3D human liver disease model** — A bioprinted primary-human-cell tissue model of MASH/NASH that develops disease-relevant fibrosis and supports histology, gene-expression analysis and compound testing.
- **MASH small-molecule program** — An unnamed, orally delivered preclinical small molecule aimed at a novel, liver-predominant target identified through Viscient’s 3D disease models; the company reported fibrosis reduction in its model in 2023.
- **Drug discovery and preclinical evaluation platform** — A workflow combining human 3D tissues with genomics, transcriptomics and metabolomics for target identification, candidate testing, in-licensing and repurposing decisions.

## Achievements

- Published a peer-reviewed 2024 study showing that bioprinted tissue made from MASH-diseased donor cells developed increased fibrosis versus healthy-donor tissue without artificial disease-inducing agents.
- Reported in 2023 that its model reproduced the clinical direction of selected successful and failed MASH compounds in retrospective testing.
- Identified an unnamed oral small-molecule MASH candidate from a target discovered primarily with 3D tissue models and advanced it to preclinical study.
- Secured a perpetual, worldwide, paid-up, non-exclusive license to specified Organovo bioprinting patents and know-how for drug discovery and research uses.
- Built a scientific advisory board that includes liver specialists David A. Brenner and Rohit Loomba.

## Latest updates

- **2026-03** — A public VivoSim filing continued to identify Viscient as an active related party focused on 3D tissue technology and multi-omics, with ongoing facility, equipment and service relationships.
- **2024-03** — The American Journal of Pathology published Viscient-supported research on hepatic stellate and sinusoidal endothelial cells in a primary-human-cell 3D NASH model.
- **2024-01** — Viscient announced the peer-reviewed validation of its MASH liver-fibrosis phenotype with collaborators at UC San Diego, Sanford Burnham Prebys and Salk.
- **2023-05** — The company announced an unnamed oral small-molecule MASH candidate discovered primarily using 3D bioprinted disease models.

## Links

- Website: https://www.viscientbiosciences.com
- LinkedIn: https://www.linkedin.com/company/viscient-biosciences
- Twitter/X: https://twitter.com/OrganovoFounder

---

Profile page: https://yespress.io/viscient-bio-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-22